Intercalators as Anticancer Drugs
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Intercalators are the most important group of compounds that interact reversibly with the DNA double helix. Some of them are valuable drugs currently used for the treatment of ovarian and breast cancers and acute leukemias, while many others are in different phases of clinical trials. Intercalating agents share common structural features such as the presence of planar polyaromatic systems which bind by insertion between DNA base-pairs, with a marked preference for 5'-pyrimidine-purine-3' steps. The chromophores are linked to basic chains that might also play an important role in the affinity and selectivity shown by these compounds. Bisintercalators have two potential intercalating ring systems connected by linkers which can vary in length and rigidity. Nowadays it is well accepted that the antitumor activity of intercalators is closely related to the ability of these compounds to stabilize the DNA-intercalator-topoisomerase II ternary complex. In this work we have carried out a revision of small organic molecules that bind to the DNA molecule via intercalation, and exert their antitumor activity through a proven topoisomerase II inhibition. We have tried to give a general overview of the most recent results in this area, paying special attention to compounds that are currently under clinical trials. Among those are naphthalimides, a group of compounds that has been developed in our laboratory since the 70's.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of Nucleic Acid Structure
(2008) · Elsevier eBooks · doi:10.1016/b978-0-12-369507-9.x5001-8 · Cited by 4,504
Nucleic acids in chemistry and biology
Blackburn, G. M., Egli, M., Gait, M. J., & Watts, J. K. (1992) · International Journal of Biochemistry · doi:10.1016/0020-711x(92)90049-7 · Cited by 465
Naphthalimides as Anticancer Agents: Synthesis and Biological Activity
Brana, M., & Ramos, A. (2001) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011013354624 · Cited by 281
Self-citation
Cited by
Estimates of the Ab Initio Limit for π−π Interactions: The Benzene Dimer
Sinnokrot, M. O., Valeev, E. F., & Sherrill, C. D. (2002) · Journal of the American Chemical Society · doi:10.1021/ja025896h · Cited by 1,339
Artesunate Induces ROS-Mediated Apoptosis in Doxorubicin-Resistant T Leukemia Cells
Efferth, T., Giaisi, M., Merling, A., Krammer, P. H., & Li-Weber, M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000693 · Cited by 256
Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy
Misra, R., & Sahoo, S. K. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.11.010 · Cited by 219
Arjmand, F., & Aziz, M. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.05.006 · Cited by 204
Effects of anticancer drugs on transcription factor–DNA interactions
Gniazdowski, M., Denny, W. A., Nelson, S. M., & Czyz, M. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.471 · Cited by 41
“Additional stabilisation of the complexes can be provided by interaction of side chain substituents on the drugs, which may H-bond to adjacent DNA elements in either groove (usually the minor groove), and which may also contribute to the entropic stabilisation [16-18].”
Background
Metadata
- Authors
- Brana, M. F., Cacho, M., Gradillas, A., de Pascual-Teresa, B., & Ramos, A.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2001-11-01
- Volume
- 7
- Issue
- 17
- Pages
- 1745-80
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2139138867
- Cited by
- 445
- References
- 3
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.